Chemical modification of the multitarget neuroprotective compound fisetin

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 378-389

  Chiruta, Chandramouli ^a   Schubert, David ^a   Dargusch, Richard ^a   Maher, Pamela ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,4 DIHYDROXYPHENYL) 1 (2 HYDROXY 4,5 DIMETHYLPHENYL)PROP 2 EN 1 ONE; 3 HYDROXY 2 [3 HYDROXY 4 (PYRROLIDIN 1 YL)PHENYL] 4H BENZO[H]CHROMEN 4 ONE; 4 [4 (CYCLOPENTYLOXY)QUINOLIN 2 YL)BENZENE 1,2 DIOL; FISETIN; FLAVONOL DERIVATIVE; GLUTATHIONE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; MOUSE; NEUROPROTECTION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CELL LINE; CELL SURVIVAL; CHALCONES; FLAVONOIDS; GLUTATHIONE; HUMANS; MICE; MICROGLIA; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84855854014     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2012563     Document Type: Article

References (44)

1. Véronique, L.; Roger, V. L.; Go, A. S.; Lloyd-Jones, d. M.; Adams, R. J.; Berry, J. D.; Brown, T. M.; Carnethon, M. R.; Dai, S.; Simone, G.; Ford, E. S.; Fox, C. S.; Fullerton, H. J.; Gillespie, C.; Greenlund, K. J.; Hailpern, S. M.; Heit, J. A.; Ho, P. M.; Howard, V. J.; Kissela, B. M.; Kittner, S. J.; Lackland, D. T.; Lichtman, J. H.; Lisabeth, L. D.; Makuc, D. M.; Marcus, G. M.; Marelli, A.; Matchar, D. B.; McDermott, M. M.; Meigs, J. B.; Moy, C. S.; Mozaffarian, D.; Mussolino, M. E.; Nichol, G.; Paynter, N. P.; Rosamond, W. D.; Sorlie, P. D.; Stafford, R. S.; Turan, T. N.; Turner, M. B.; Wong, N. D.; Wylie-Rosett, J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circulation 2011, 123, e18-e209
2. Donnan, G. A.; Fisher, M.; Macleod, M.; Davis, S. M. Stroke Lancet 2008, 371, 1612-1623
3. Lipton, P. Ischemic death in brain neurons Physiol. Rev. 1999, 79, 1431-1568
4. Pandya, R. S.; Mao, L.; Zhou, H.; Zhou, S.; Zeng, J.; Popp, A. J.; Wang, X. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent. Nerv. Syst. Agents Med. Chem. [Online early access]. DOI: 10.2174/187152411796011321, Apr 27, 2011.
5. Green, A. R.; Shuaib, A. Therapeutic strategies for the treatment of stroke Drug Discovery Today 2006, 11, 681-693
6. Maher, P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin Genes Nutr. 2009, Sep, 10
7. Maher, P.; Salgado, K. F.; Zivin, J. A.; Lapchak, P. A. A novel approach for new neuroprotective compounds for the treatment of dtroke Brain Res. 2007, 1173, 117-125
8. Sogawa, S.; Nihro, Y.; Ueda, H.; Izumi, A.; Miki, T.; Matsumoto, H.; Satoh, T. 3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors J. Med. Chem. 1993, 36, 3904-3909
9. Chu, H. W.; Wu, H. T.; Lee, J. Y. Regioselective hydroxylation of 2-hydroxychalcones by dimethyldioxirane towards polymethoxylated flavonoids Tetrahedron 2004, 60, 2647-2655
10. Cabrera, M.; Simoens, M.; Falchi, G.; Lavaggi, M. L.; Piro, O. E.; Castellano, E. E.; Vidal, A.; Azqueta, A.; Monge, A.; López de Ceráin, A.; Sagrera, G.; Seoane, G.; Cerecettoa, H.; Gonzáleza, M. Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships Bioorg. Med. Chem. 2007, 15, 3356-3367
11. Horie, T.; Tsukayama, M.; Kourai, H.; Yokoyama, C.; Furukawa, M.; Yoshimoto, T.; Yamamoto, S.; Watanabe-Kohno, S.; Ohataf, K. Syntheses of 5,6,7- and 5,7,8-trioxygenated 3′,4′-dihydroxyflavones having alkoxy groups and their inhibitory activities against arachidonate 5-lipoxygenase J. Med. Chem. 1986, 29, 2256-2262
12. Qin, C. X.; Chen, X.; Hughes, R. A.; Williams, S. J.; Woodman, O. L. Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity J. Med. Chem. 2008, 51, 1874-1884
13. Wang, Y.; Peng, C.; Liu, L.; Zhao, J.; Su, L.; Zhu, Q. Sulfuric acid promoted condensation cyclization of 2-(2-(trimethylsilyl) ethynyl) anilines with arylaldehydes in alcoholic solvents: an efficient one-pot synthesis of 4-alkoxy-2-arylquinolines Tetrahedron Lett. 2009, 50, 2261-2265
14. Pangalos, M. N.; Schechter, L. E.; Hurko., O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition Nat. Rev. Drug Discovery 2007, 6, 521-532
15. Winkler, B. S.; Sauer, M. W.; Starnes, C. A. Modulation of the Pasteur effect in retinal cells: implications for understanding compensatory metabolic mechanisms Exp. Eye Res. 2003, 76, 715-723
16. Reshef, A.; Sperling, O.; Zoref-Shani, E. Activation and inhibition of protein kinase C protect rat neuronal cultures against ischemia-reperfusion insult Neurosci. Lett. 1997, 238, 37-40
17. Sperling, O.; Bromberg, Y.; Oelsner, H.; Zoref-Shani, E. Reactive oxygen species play an important role in iodoacetate-induced neurotoxicity in primary rat neuronal cultures and in differentiated PC12 cells Neursci. Lett. 2003, 351, 137-140
18. Rego, A. C.; Areias, F. M.; Santos, M. S.; Oliveira, C. R. Distinct glycolysis inhibitors determine retinal cell sensitivity to glutamate-mediated injury Neurochem. Res. 1999, 24, 351-358
19. Sigalov, E.; Fridkin, M.; Brenneman, D. E.; Gozes, I. VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury J. Mol. Neurosci. 2000, 15, 147-154
20. Reiner, P. B.; Laycock, A. G.; Doll, C. J. A pharmacological model of ischemia in the hippocampal slice Neurosci. Lett. 1990, 119, 175-178
21. Biraboneye, A. C.; Madonna, S.; Laras, Y.; Maher, P.; Kraus, J. L. Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity J. Med. Chem. 2009, 52, 4358-4369
22. Biraboneye, A. C.; Madonna, S.; Maher, P.; Kraus, J. L. Neuroprotective effects of N -alkyl-1,2,4-oxadiazolidine-3,5-diones and their corresponding synthetic intermediates N -alkylhydroxylamines and N -1-alkyl-3-carbonyl-1- hydroxyureas against in vitro cerebral ischemia Chem. Med. Chem. 2010, 5, 79-85
23. Lipton, P. Ischemic death in brain neurons Physiol. Rev. 1999, 79, 1431-1568
24. Reiner, P. B.; Laycock, A. G.; Doll, C. J. A pharmacological model of ischemia in the hippocampal slice Neurosci. Lett. 1990, 119, 175-178
25. Taylor, B. M.; Fleming, W. E.; Benjamin, C. W.; Wu, Y.; Mathews, R.; Sun, F. F. The mechanism of cytoprotective action of lazaroids: I. Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion J. Pharmacol. Exp. Ther. 1996, 276, 1224-1231
26. Winkler, B. S.; Sauer, M. W.; Starnes, C. A. Modulation of the Pasteur effect in retinal cells: implications for understanding compensatory metabolic mechanisms Exp. Eye Res. 2003, 76, 715-723
27. Sperling, O.; Bromberg, Y.; Oelsner, H.; Zoref-Shani, E. Reactive oxygen species play an important role in iodoacetate-induced neurotoxicity in primary rat neuronal cultures and in differentiated PC12 cells Neursci. Lett. 2003, 351, 137-140
28. Sperling, O.; Bromberg, Y.; Oelsner, H.; Zoref-Shani, E. Reactive oxygen species play an important role in iodoacetate-induced neurotoxicity in primary rat neuronal cultures and in differentiated PC12 cells Neursci. Lett. 2003, 351, 137-140
29. Gelderblom, M.; Leypoldt, F.; Steinbach, K.; Behrens, D.; Choe, C. U.; Siler, D. A.; Arumugam, T. V.; Orthey, E.; Gerloff, C.; Tolosa, E.; Magnus, T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke Stroke 2009, 40, 1849-1857
30. Pandya, R. S.; Mao, L.; Zhou, H.; Zhou, S.; Zeng, J.; Popp, A. J.; Wang, X. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent. Nerv. Syst. Agents Med. Chem. [Online early access]. DOI: 10.2174/187152411796011321, Apr 27, 2011.
31. Lewerenz, J.; Dargusch, R.; Maher, P. Lactacidosis modulates glutathione metabolism and oxidative glutamate toxicity J. Neurochem. 2010, 113, 502-504
32. Tan, S.; Schubert, D.; Maher, P. Oxytosis: a novel form of programmed cell death Curr. Top. Med. Chem. 2001, 1, 497-506
33. Maher, P. A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives Free Radical Res. 2006, 40, 1105-1111
34. Zheng, L. T.; Ock, J.; Kwon, B. M.; Suk, K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity Int. Immunopharmacol. 2008, 8, 484-494
35. Sagara, Y.; Vanhnasy, J.; Maher, P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation J. Neurochem. 2004, 90, 1144-1155
36. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583
37. Lewerenz, J.; Maher, P. Control of redox state and redox signaling by neural antioxidant systems Antioxid. Redox Signaling 2011, 14, 1449-1465
38. Shia, C. S.; Tsai, S, Y.; Kuo, S. C.; Hou, Y, C.; Chao, P. D. Metabolism and pharmacokinetics of 3,3′,4′,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites J. Agric. Food Chem. 2009, 57, 83-89
39. Maher, P.; Dargusch, R.; Bodai, L.; Gerard, P. E.; Purcell, J. M.; Marsh, J. L. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntingtons disease Hum. Mol. Genet. 2011, 20, 261-270
40. Maher, P.; Dargusch, R.; Ehren, J. L.; Okada, S.; Sharma, K.; Schubert, D. Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes PLoS One 2011, 6, e21226
41. Maher, P. A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives Free Radical Res. 2006, 40, 1105-1111
42. Schreiber, E.; Matthias, P.; Muller, M. M.; Schaffner, W. Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells Nucleic Acids Res. 1989, 17, 6419
43. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs NeuroRx 2005, 2, 541-553
44. Lloyed, E. J.; Andrews, P. R. A common structural model for central nervous system drugs and their receptors J. Med. Chem. 1986, 29, 453-462